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Abstract
Background: Cerebral malaria is a severe neurological form of malaria that affects the central nervous system,
is caused by Plasmodium falciparum parasitemia, and has a common complication of seizures and coma
especially in children. In African children under the age of 5 it is the leading cause of death; over one million
children in sub-Saharan Africa alone die or are disabled as a result of cerebral malaria annually. Seizures are a
frequent complication of cerebral malaria and are associated with an increased risk of death and neurological
sequelae including epilepsy, as well as a much broader range of motor and cognitive impairments. These
impairments severely impact a child’s lifelong educational and social potential. Phenobarbital is an effective
anti-convulsant that both controls and prevents seizures, is widely available in resource poor countries and can
be delivered in a single IM dose for ease of rapid delivery. The objective is to assess the efficacy of
phenobarbital when given as anti-convulsant prophylaxis in children with cerebral malaria.
Methods: An exhaustive search of available medical literature was performed using CINAHL, MEDLINE,
Cochrane Database, and the African Index Medicus. The search terms included “cerebral malaria”, “children”,
“Phenobarbital”, “prophylaxis” and “seizure”. All full text articles in the English language were used. Meta-
analysis and case studies were excluded. Three articles were chosen for review.
Results: Overall it was found in all the studies that the prophylactic use of phenobarbital (PB) in children with
cerebral malaria decreased the number of prolonged seizures they had while in the acute stage of parasitemia.
It was also found that malaria treatment with quinine does not potentiate or interact with the PB, and that PB
does not prolong coma or delay the recovery of children with cerebral malaria, nor does PB have any long
term negative cognitive effects in children. However, the dose and route of administration of PB in children
remains a controversy. One study that suggested that PB 20mg/kg intramuscularly was effective, but the
children in this study receiving treatment had a mortality rate double the control group, likely due to anti-
convulsant polypharmacy. Another study recommended 10mg/kg IM dosing but it was found to not be
effective in controlling seizures. One study showed that 15mg/kg intravenously was effective, and a parallel
simulated study recommended that the same dose given IM would be just as effective, although there is no
actual data to support this.
Conclusion: The use of phenobarbital as a prophylactic anti-convulsive in children that have cerebral malaria
is an effective way of decreasing acute seizure activity and therefore reducing the risk of long term neurological
sequelae in this population. Standardized dosing and route of administration of phenobarbital for this
application have not yet been established however, and more randomized controlled trials need to be
completed before recommendations can be made.
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Abstract   
 
Background:  Cerebral malaria is a severe neurological form of malaria that affects the 
central nervous system, is caused by Plasmodium falciparum parasitemia, and has a 
common complication of seizures and coma especially in children.  In African children 
under the age of 5 it is the leading cause of death; over one million children in sub-
Saharan Africa alone die or are disabled as a result of cerebral malaria annually. Seizures 
are a frequent complication of cerebral malaria and are associated with an increased risk 
of death and neurological sequelae including epilepsy, as well as a much broader range of 
motor and cognitive impairments. These impairments severely impact a child’s lifelong 
educational and social potential. Phenobarbital is an effective anti-convulsant that both 
controls and prevents seizures, is widely available in resource poor countries and can be 
delivered in a single IM dose for ease of rapid delivery. The objective is to assess the 
efficacy of phenobarbital when given as anti-convulsant prophylaxis in children with 
cerebral malaria. 
 
Methods:  An exhaustive search of available medical literature was performed using 
CINAHL, MEDLINE, Cochrane Database, and the African Index Medicus. The search 
terms included “cerebral malaria”, “children”, “Phenobarbital”, “prophylaxis” and 
“seizure”. All full text articles in the English language were used. Meta-analysis and case 
studies were excluded. Three articles were chosen for review. 
 
Results: Overall it was found in all the studies that the prophylactic use of phenobarbital 
(PB) in children with cerebral malaria decreased the number of prolonged seizures they 
had while in the acute stage of parasitemia. It was also found that malaria treatment with 
quinine does not potentiate or interact with the PB, and that PB does not prolong coma or 
delay the recovery of children with cerebral malaria, nor does PB have any long term 
negative cognitive effects in children. However, the dose and route of administration of 
PB in children remains a controversy. One study that suggested that PB 20mg/kg 
intramuscularly was effective, but the children in this study receiving treatment had a 
mortality rate double the control group, likely due to anti-convulsant polypharmacy. 
Another study recommended 10mg/kg IM dosing but it was found to not be effective in 
controlling seizures. One study showed that 15mg/kg intravenously was effective, and a 
parallel simulated study recommended that the same dose given IM would be just as 
effective, although there is no actual data to support this.  
 
Conclusion:  The use of phenobarbital as a prophylactic anti-convulsive in children that 
have cerebral malaria is an effective way of decreasing acute seizure activity and 
therefore reducing the risk of long term neurological sequelae in this population. 
Standardized dosing and route of administration of phenobarbital for this application 
have not yet been established however, and more randomized controlled trials need to be 
completed before recommendations can be made. 
 
Keywords:  Cerebral Malaria, Anti-convulsant Prophylaxis, Seizure, Children, 
Phenobarbital  
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Efficacy of Phenobarbital as a Prophylactic Anti-Convulsive in African Children 
with Cerebral Malaria 
 
BACKGROUND 
 Malaria is one of the most common parasitic diseases and a major public 
health problem worldwide, with the highest concentration of morbity and mortality in 
Africa.1 Cerebral malaria (CM) is a severe neurological form of malaria that affects the 
central nervous system, is caused by Plasmodium falciparum parasitemia, and has a 
common complication of seizures and coma especially in children.  Children less than 5 
years of age are particularly susceptible to developing cerebral malaria because of low 
immunity levels.2 Over one million children in sub-Saharan Africa alone die or are 
disabled as a result of cerebral malaria annually, and 40% of all public health expenditure 
in Africa goes towards the prevention and treatment of malaria.3   Cerebral malaria is 
seen frequently, attributing to approximately 10-15% of all hospital admissions in sub-
Saharan Africa4, but is not treated consistently. In this most endemic area of the world, it 
is important to assess what can be done to improve the outcomes for these children.   
Seizures are a frequent complication of cerebral malaria and are associated with 
an increased risk of death and neurological sequelae such as hemiplegia, spastic 
quadriplegia, visual impairment, speech delay, and epilepsy as well as a much broader 
range of motor and cognitive impairment.5,6 These impairments severely impact a child’s 
lifelong educational and social potential. A recent study concluded that as many as 1 in 4 
children who survive CM develop these long term neurological deficits.7  
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  In sub-Saharan Africa, where over 80% of malaria cases and 90-95% of deaths 
worldwide occur, cerebral malaria accounts for an estimated 600,000 children under the 
age of 5 annually. Of these children, about 100,000 die, consistent with a mortality rate of 
almost 20%, and an additional 20,000 children experience long term neurological 
sequelae, particularly epilepsy.1,4,6-9 This number may be under reported due to lack of 
routine long term follow up, social pressure, and lack of resources. Epilepsy is still 
heavily stigmatized in African countries, as are most neurological and physical 
disorders.10 Therapies provided by traditional healers are the mainstay of treatment for 
many.11-13  Additionally, many people may not have been well educated on the signs, 
symptoms, and overall risks of their children developing cerebral malaria. The most 
frequently reported perceived causes of convulsions reported by respondents in a vignette 
study were phlegm, worm infections, mosquito bites, eating too much fatty or oily food, 
heat from the sun, and magico-religious causes.14 In fact, many studies done across sub-
Saharan Africa show that spiritual forces dominate the perceived causes for children who 
have seizures.14 The lack of education and treatment by traditional healers has clearly 
decreased the timeliness of acute care needs and complicated the overall outcome of 
these children.  
 Phenobarbital is a barbituate that has been used since the early 1900s, it is the 
oldest and most widely used medication used to control seizures worldwide, and is a core 
medicine listed in the WHO Model List of Essential Medicines for developing countries. 
It is one of the longest acting anticonvulsant medications available, and per most recent 
data found online at www.Pharmacychecker.com, PB can be purchased in the United 
States for $.06 per pill, as opposed to diazepam at $.12 per pill or phenytoin at $.21 per 
 9 
pill. In a follow up study aimed at assessing developmental outcomes in children who had 
received PB as an anticonvulsant prophylaxis in CM, it was found that PB showed no 
indication of producing long term negative cognitive effects.15 Additionally, PB does not 
potentiate or change the efficacy of concurrent quinine administration, necessary for the 
treatment of malaria.16 
Diazepam is considered a first line anti-convulsant medication worldwide. While 
Diazepam is useful in status epilepticus, it does not offer any prophylactic benefit, 
particularly in a single dose administration.17 There is also a difference in diazepam 
efficacy seen in the comparison between patients with and without parasitaemia as a 
whole, potentially because patients with cerebral malaria have reduced plasma and CSF 
concentrations of histidine, an amino acid which is an important constituent of the 
GABA-A receptor that may influence benzodiazepine ligand binding. This could be a 
plausible explanation of diazepam's decreased binding affinity at the GABA-A receptors 
or its reduced clinical efficacy in patients with parasitaemia.27 Thus diazepam may be less 
efficacious in controlling seizures in children with malaria. It has been shown that PB is 
highly effective in treating status epilepticus without an increase in respiratory depression 
or hypotension.18,19 Buccal midazolam, intranasal lorazepam, IM paraldehyde, and rectal 
diazepam have also been studied as effective means for treatment and control of 
prolonged seizures but none have been studied as a prophylaxis, and the need for 
refrigeration with the lorazepam and paraldehyde make those options less feasible. 
Buccal midazolam is unattractive due to price, and the route of the diazepam 
administration has socially unacceptable associations.20 Previous findings in Kenyan 
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children also indicated that rectal absorption of parenteral diazepam is erratic and 
terminates less seizures than intravenous administration.17 
  
METHODS 
An exhaustive literature search was conducted using the MEDLINE, CINAHL, 
Cochrane Database, and the African Index Medicus. The search terms included “cerebral 
malaria”, “children”, “Phenobarbital”, “prophylaxis” and “seizure”. Only full text articles 
in the English language were used. Meta-analysis and case studies were not included. 
Subsequent examination of bibliographic entries in retrieved works provided additional 
studies for consideration. The results of the remaining studies were then compiled and 
examined. 
Inclusion/ Exclusion Criteria 
Exclusion criteria included any study with adults and any study not done in 
Africa.  Also excluded was any study that gave seizure prophylaxis other than PB while 
hospitalized, such as diazepam or phenytoin. All the studies examined here excluded 
children with a previous history of epilepsy and any child who had received any PB prior 
to admission. The population analyzed was hospitalized children living in endemic P. 
falciparum areas who received prophylactic PB versus those children who were not given 
any PB prophylaxis, and the outcomes measured included subsequent seizure activity, 
mortality rates in both groups, and the potential to develop long term neurological 
sequelae. All the studies reviewed defined children with CM as prostrate, in an 
unarousable coma (Blantyre score of 3 or less- see Appendix A for detailed explanation), 
and with P. falciparum parasitemia visible with light microscopy.21 Any study with 
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dosing or route variations of PB was included. Studies that gave additional treatment for 
cerebral malaria such as quinine sulfate, paracetamol, or antibiotics were included, as it 
has been shown that these polypharmacies are necessary for effective cerebral malaria 
treatment and do not decrease or potentiate the efficacy of the PB.22 There was no 
exclusion on the age of the article, as PB has been used for a century as an 
anticonvulsant, although the majority of the data collected was from the last decade.  
Critical Appraisal   
The studies were subsequently rated and assessed for quality using an original 
scoring criteria. Because there was only one randomized controlled study and a number 
of blinded but open trials, all articles were included for consideration despite a lower 
score. (see Table 1). A relative score representing quality and validity was assigned to 
each article. Higher scores were awarded for prospective and controlled investigations, 
and for large sample populations. Lower scores were earned by those with minimal effort 
to minimize confounding factors, and those with smaller experimental groups. The 
overall average age of the child participants in all of the studies examined in this review 
was 30 months of age. However, the age of participants ranged from approximately 9 
months to 13 years of age in the three studies.  
 
RESULTS 
A total of 3 articles which met all of the inclusion criteria were examined in this 
review. The largest group studied consisted of 340 children with CM5, and the smallest 
group consisted of 1216.  Each study defined CM in the same manner, a child with a 
Blantyre coma score of 3 or less with a positive malaria blood test. The shortest study 
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lasted only as long as the children were acutely hospitalized (a few days)16, and the 
longest study participants were re-examined during a follow up period of three months5. 
One study included in this review was a randomized, controlled trial, although not double 
blinded.5 One trial was an open label, non-randomized study16, and one was a double 
blinded placebo controlled trial.22  All three studies compared African children who 
received PB prophylactically during an acute hospital admission for CM. All study 
participants had written informed parental consent for treatment.   
In the largest study by Crawley et al (2000)5, a single PB dose of 20 mg/kg IM 
was used as anticonvulsant prophylaxis. Those results were compared with a pre-
screened group of Kenyan children who were initially recruited to assess the clinical 
tolerance of PB 20mg/kg given by continuous IV infusion over a four hour time frame. 
There were 170 children from Kilifi District Hospital in both the treatment and control 
group. In this study, blood samples for PB measurements were taken from all patients at 
1, 2, 4, 8, 12, 24, 36, and 48 hours. These samples were all sent to an independent lab in 
Nairobi, Kenya for analysis. Parasite counts were repeatedly taken every 8h until 
discharge, death, or parasitemia clearance. All the children in this study received anti-
malarial therapy in the form of IV quinine dihydrochloride, with a loading dose of 
15mg/kg, and subsequent maintenance doses of 10mg/kg every 12h. IV fluids, blood 
transfusions, and treatment for hypoglycemia were given as clinically indicated and all 
vital signs were recorded. Any child with a fever above 38.5 C was treated with 
paracetamol (acetamenophen) 15mg/kg rectally every 6h. The number and duration of 
seizures were recorded at 5, 15, and 30 minutes. Seizures lasting longer than 5 minutes 
were treated with diazepam 0.3mg/kg IV injection, up to 2 doses, then changed to 
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paraldehyde 0.2mg/kg IM given every 5, 15, 30, and 45 minutes as needed. This study 
found that the median time to maximum blood concentration of PB was 4 hours. 
Concentrations were maintained above 15mg/L, within the optimal range of 10-30 mg/L, 
for at least 48 hours, which is considered effective for seizure prophylaxis.(1-18) The 
placebo and PB groups showed no difference in the median time to parasite clearance 
(p=0.21), and there was no difference in the groups in the time taken to recover 
consciousness (p=0.39).  PB provided effective seizure prophylaxis, decreasing the 
frequency and duration of seizures by over 50% (95% CI). Fewer children who received 
the PB subsequently required further anticonvulsant medications (8.2% vs 15.9%, 
p=0.04, CI 95%). This study also had the result of the PB group with a doubled mortality 
rate of the placebo group. This was attributed by the authors to the fact that these children 
on admission were more deeply comatose, dehydrated, acidotic, and hypoglycemic than 
those who survived. The mean respiratory rate at 4 hours (also the median time to 
maximum PB concentrations) was much higher in those who died (57 vs 47, 95% CI). 
This was relevant because the majority of the children in this study who died did so from 
respiratory arrest (22 vs 11, OR 2:1, CI 95%, p=0.05). The main indicator for these 
deaths was the additional diazepam (3 or more doses) given for either pre-hospital 
treatment of seizures or for subsequent seizures after the PB had been given. The 
interaction between PB and diazepam was associated with increased risk of death ( CI 
95%) with less than 3 doses of diazepam resulting in 15% mortality rate (OR 1.9, p=0.07) 
and with more than 3 doses of diazepam resulting in a 62% mortality rate (OR 31.7, 
p=0.001).  
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  Winstanley et al (1992)22, measured a single dose of PB given 10mg/kg IM 
specifically within two hours of admission. There were 14 Kenyan children from Kilifi 
District Hospital in the treatment group and 39 children in the control group in this study. 
These children were studied in two groups; one that looked at children with convulsions 
with CM as the treatment group, the other with children with convulsions (>2 in the 24 
hours prior to admission) who were aparasitic as the control group. The children with CM 
were given appropriate anti-malarial treatment with quinine 20mg/kg IV loading dose 
followed by 10mg/kg maintenance doses every 12h. Patients were treated for fever and 
hypoglycemia under the same guidelines as the Crawley et al study.  The aparasitic 
children were treated with appropriate antibiotics.  All seizures over 5 minutes in duration 
were treated with diazepam 0.3mg/kg IV. Blood sampling for PB measurements was 
done at an interval of 0.5, 1, 1.5, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144, and 168 hours after 
dosing. These samples were sent to the same lab in Nairobi as the Crawley et al study for 
analysis. The control group in this study received all the same therapy with the only 
exception being the single dose of PB. No follow up beyond hospital discharge was 
performed. Results from this study showed that the mean time to optimal PB blood 
concentrations in the treatment group of 4 hours vs. 3 hours in the control group was 
noted. An improvement in motor response score at a mean time of 21 hours after 
admission for the treatment group vs 22 hours in the control group. There was no 
difference in the groups in the incidence of seizures during admission (2.5 vs 1.5), or the 
incidence of neurological sequelae (2 vs 2). Mortality between the groups showed no real 
significance (2 (14) vs 9 (23)). 
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 The third study by Kokwaro et al (2002)16 looked at the dose of PB in the same 
population at the Kilifi District Hospital in Kenya. A 15mg/kg dose of PB was given IV, 
infused over 20 minutes, followed by maintenance doses of 5mg/kg at 24 and 48h after 
the loading dose. Twelve children were in the treatment group-this study had no control 
group. Vital signs were recorded every 4 hours. Any seizure activity after the dose of PB 
was given was treated with diazepam, paraldehyde, or phenytoin. Blood samples for PB 
concentrations were collected at 10, 20, 25, 20, 40, and 60 minutes, and again at 2, 6, 12, 
24, 36, 48, 54, 60, and 72 hours after the loading dose that were analyzed in house. All 
patients in this study were asked to come back for a three month follow up appointment. 
Results found that optimal PB blood concentrations (greater than 10mg/L) were achieved 
within 10 minutes of dosing, and maintained for at least 48 hours. This study also 
simulated a 2.5mg/kg maintenance dose of PB at 24 and 48 hours that appeared to show 
equal efficacy with 95% CI. Convulsions were controlled in 66% of the treatment group, 
and there were no cases of neurological sequelae on follow up. There was no significant 
difference in biochemical measurements on admission between these children and those 
who received treatment and whose seizures were not controlled with PB. 
  
DISCUSSION 
 Upon reviewing these studies, it seems apparent that using PB as a prophylactic 
anticonvulsant in children with CM is an effective way of reducing subsequent seizures, 
possibly ensuring a more rapid recovery from a comatose state and a way to decrease 
mortality as long as precautions are taken when additional anticonvulsant medications are 
given. No evidence was found that PB prolonged coma.23 Diazepam, phenytoin, and 
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midazolam are newer, more effective medications, some with a decreased risk of 
respiratory depression, that are considered to be first line treatment in Africa for these 
patients.  These medications are not always available because of their overall worldwide 
supply, cost, and their route of administration may not be socially acceptable.20 PB has 
been around since the early1900s, is widely available worldwide, and is considered a 
cheap, safe, long-acting medication with excellent bioavailability23 after IM 
administration to be given for seizures, and accordingly is used most often in malaria 
endemic regions.17 In CM, children tend to have prolonged seizures that are associated 
with an increased risk of death and long term neurological sequelae.1,3,6-9,20 
The efficacy of PB as a prophylactic anti-convulsant in patients with CM is 
apparent, but potentially based solely on its dose and route of administration. IV 
administration is the most rapid way to bring blood concentrations of PB up to optimal 
levels to reduce further seizure activity. However, in many places worldwide this route 
may be hampered by lack of supplies, time, or qualified staff. IM administration is the 
most simple form, and at a dose of 20mg/kg it proved very effective.5 In a simulated 
profile, it was suggested that a 15mg/kg IM dose would also be effective.16 A 10mg/kg 
IM dose was found not to be effective 22 and although in Thailand one study by White et 
al23 found a smaller dose of 3.5kg/mg effective, those results did not translate over to a 
pediatric sub-Saharan Africa population which is possibly due to the difference in the 
pathophysiology of CM between children and adults. Additionally of interest, PB was not 
found to potentiate or change the efficacy of quinine absorption in children with CM, or 
vice versa.22 In a different study based on traumatic brain injuries, it was shown that the 
use of prophylactic anti-epileptic drugs were effective at preventing early and immediate 
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provoked seizures when used briefly at the outset of the initial trauma26, which could be 
applied to those children with acute cerebral malaria. 
The articles included in this review reflect a broad variety of research methods in 
less than optimal conditions, and their results are of variable quality.  Limitations in these 
studies were numerous, mostly because of the small study sizes and lack of randomized 
controlled trials with significant data. In terms of global representation, only three studies 
from sub-Saharan Africa were used. It would be ideal to include more studies from Asia, 
India, and South and Central America to compare dosing recommendations and efficacy 
of PB worldwide. Practitioners who lack blood for transfusions, IV access, laboratory 
supplies to test for parasitemia, quinine, antibiotics, or dextrose solution for the 
correction of low blood counts, dehydration, infection, or hypoglycemia, would find that 
prophylactic treatment with PB would prove moot, which is frequently the case in 
developing countries where even basic medical care is often unavailable . Additional 
treatment with other anti-convulsant medications becomes a major problem because 
many healthcare facilities do not have the appropriate equipment to monitor or treat 
patients for respiratory distress.  
The onset of illness to the time of treatment also plays a critical factor in the 
efficacy of PB and overall outcome of these patients. Only one study addressed this 
problem directly,22 but did not make any further recommendations regarding prompt 
treatment after recognizing the patient was severely ill. Children have a very brief 
interlude between the time when CM symptoms first present to the time of coma, on 
average only 1-2 days.24 This problem will continue to be a major issue in developing 
countries due to difficulty accessing medical care, physically and financially. In addition, 
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appropriate and adequate nursing care is crucial to the successful outcomes of children 
with CM as nurses are often the first line component of assessment and pre-hospital 
treatment. This subjective factor is an important step in the treatment process, and is 
variable at best. It is estimated that only 24% of children under the age of 5 that present 
with a fever to hospitals in Africa receive anti-malarial treatment, even when 40% of all 
hospital admissions for children are for malaria.3 A recent statistic analysis reports that 
worldwide malaria morbidity and mortality is under-represented, and in many sub-
Saharan African countries the overall death rate in children under 5 has been rising since 
1999.3 Though this review is limited by the fact that a countless number of confounding 
and modifying factors are present when studying a process such as CM progression and 
prophylactic convulsion treatment in children, it does help to elucidate many of the topics 
that remain to be studied with regard to the overall health of children with CM 
worldwide. Complicating effects are the variability in which CM manifests in children 
overall. Some children experience severe anemia or hypoglycemia, and some do not. The 
effects of variables concerning each child’s overall nutritional status or home 
environment, which contribute greatly to their cognitive status, is nearly impossible to 
track. As an example, another common cause of seizures in African children is 
helminthes infection, due to lack of proper footwear, adequate food preparation, or poor 
hygiene.25 These variables may mask the benefits of the PB prophylaxis, limiting 
conclusions that might be drawn about its benefits.15 Additional confounding effects of 
these studies were lack of a true placebo group in the Kokwaro et al trial, so no 
comparisons between a treatment and control group could be made, the data collected 
was minimal. The White et al study did not differentiate the data in terms of age, so it is 
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impossible to extrapolate if the PB dose given was suitable or helpful for children, and no 
data was collected for children under 5 years of age, the most susceptible age group for 
developing CM.  
Ethical issues were problematic in this review. There is a known interaction 
between PB and diazepam that causes respiratory depression, and an increased risk of 
death.5 The only clinical significance between the groups in admission or laboratory 
findings was the mean respiratory rate because the majority of the children in this study 
who died did so from respiratory arrest. However in many of the studies, diazepam was 
given to children who experienced further convulsions after receiving PB prophylaxis, 
even in a hospital who did not have the means to provide any respiratory support or 
resuscitation. It would be beneficial to have a study done at a facility that has proper 
equipment to assess the true mortality rates of these children when all the necessary 
lifesaving resources are available. The laboratory in Nairobi where all but one of the 
blood samples from these studies was processed at is another ethical debate. It is difficult 
to know if any of the samples were contaminated or changed during their transport time, 
over an 8 hour drive, from the coast to Nairobi. It would be best to have a more 
specialized in-house lab team that could process blood samples for future studies to 
provide the purest and most timely results. 
Social stigmas and delay or lack of proper treatment due to cultural beliefs 
contribute to the dilemma of children receiving adequate care for CM. The perceived 
causes of seizures among sub-Saharan Africans are dominantly magico-religious causes, 
and many reports across sub-Saharan Africa emphasized use of traditional healers as the 
primary source of treatment for convulsions, rather than modern medical care.13 Studies 
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have shown that even among urban-dwelling Africans with epilepsy, up to 70 percent use 
traditional medicines.12 In rural regions, the population has less education and limited 
access to modern care possibly elevating this figure even further. Because concerns about 
supernatural causes of convulsions are evident, epilepsy is still heavily stigmatized in 
African countries.10 The negative impact is evident on extended family members, too. 
Families with a child suffering from epilepsy may go to great lengths to prevent the 
development of recurrent seizures in their other family members because in addition to 
their superstitions, they may believe that epilepsy is also contagious. Relating outcomes 
to timely help-seeking and malaria prevention needs to incorporate local relevance into 
the design and implementation of local program strategies. 
 
CONCLUSION 
WHO has recently implemented two programs; the Global Malaria Programme 
and the Roll Back Malaria initiative in Africa, to help prevent, more rapidly and correctly 
assess, and ultimately help cure malaria. Both programs hold promise in collecting more 
detailed information and getting more definitive education and treatment options out to 
communities and medical personnel.  Ultimately, more randomized controlled studies 
using PB specifically in a single IM dose need to be completed to provide a better 
understanding of its overall risk versus benefit in prophylactically reducing seizures in 
children with CM to determine its efficacy in the easiest, most cost-effective 
administration in developing countries. The current standard of care entails treating each 
child as individual circumstances warrant and mostly focuses on anti-malarial treatment 
as a priority. However, based on the studies reviewed here, the evidence points to the 
 21 
overall benefit of using PB as anti-convulsant prophylaxis, especially when seen in the 
incidence of helping to prevent long term neurological sequelae. This improved treatment 
could positively affect the lives of millions of children not just in Africa, but worldwide. 
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Table 1 –Matrix of Reviewed Literature 
Author and 
Study Type 
Patients/  
Population 
Comparison Outcome(s) Validity-
Original 
Scoring 
 
Comments 
Crawley et.al 
(2000)5  
Randomized 
Controlled 
Study 
340 children 
in tropical 
Africa; 170 
in treatment 
group, 170 
in control 
group 
Children 
given 
Phenobarbital 
during acute 
episode of 
cerebral 
malaria vs. no 
Phenobarbital. 
Phenobarbital 
use at 
20mg/kg IM 
proved 
effective 
prophylaxis. 
Doubled 
mortality of 
patients in the 
treatment 
group 
however, 
possibly due 
to dosing and 
polypharmacy. 
4/5 Study was not double blinded. Safe and 
effective dosing of Phenobarbital needs to 
be addressed as well as administration of 
drug. 
Kokwaro, 
et. al 
(2002)16 
Open label 
non-
randomized 
study 
12 children 
in tropical 
Africa; no 
control 
group. 
No real 
comparison 
group. 
Phenobarbital 
use in 
15mg/kg IV 
dose proved 
effective at 
seizure 
prophylaxis, 
simulated IM 
dose may also 
work. 
3/5 Study was not randomized, or double 
blinded. H & P screening only for 
participants. Very small treatment group, 
larger more complete studies needed, but a 
good start at narrowing down dosing and 
route. 
Winstanley, 
et. al 
(1992)22 
Open label 
non-
randomized 
study 
 
 
 
 
14 children 
in tropical 
Africa in 
treatment 
group, 39 
children in 
control 
group. 
Children 
given 
Phenobarbital 
during acute 
episode of 
cerebral 
malaria vs. no 
seizure 
prophylaxis. 
PB use in 
10mg/kg IM 
dose proved 
to be 
ineffective, 
treatment 
changed to 
15mg/kg mid-
study . 
3/5 Study was not randomized or double 
blinded. Small treatment group and control 
group, larger more complete studies needed. 
Study showed that QS did not potentiate 
any Phenobarbital activity, and that dosing 
was too low at 10mg/kg.  
Ogutu, et al. 
(2004) 
Treatment 
Paradigm 
for Seizure 
management 
in children 
with 
cerebral 
malaria 
 
Kenya 
Medical 
Research 
Institute  
  1/5 Not an actual study, but treatment 
recommendations based on previous 
studies. 
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Figure 1: Malaria distribution in Africa, courtesy of MARA/ARMA 
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Appendix A :  Blantyre Coma Scale24 
 
 
The following coma scale – the “Blantyre coma scale” – is modified from the widely 
used Glasgow coma scale (1974), is applicable to children, including those who have not 
learned to speak. 
 
 
 
 
Best motor response:   localizes painful stimulus           2 
withdraws limb from paina          1 
nonspecific or absent responseb    0 
 
Verbal response:    appropriate cry         2 
moan or inappropriate cry            1 
none                                              0 
 
Eye movements:    directed(e.g. follows mother’s face)   1 
not directed     0 
 
Score:          Total 0–5 
 
A state of unrousable coma is reached at a score of <3.  This scale can be used repeatedly 
to assess improvement or deterioration. 
 
a Rub knuckles on patient’s sternum. 
b Firm pressure on thumbnail bed with horizontal pencil 
  
